Gentian Diagnostics ASA

Board/Management Information • Mar 8, 2017

GENTIAN DIAGNOSTICS APPOINTS DR ALEKSANDRA MANDIC HAVELKA AS MANAGING DIRECTOR OF ITS SWEDISH SUBSIDUARY: GENTIAN DIAGNOSTICS AB

GENTIAN DIAGNOSTICS APPOINTS DR ALEKSANDRA MANDIC HAVELKA AS MANAGING DIRECTOR OF ITS SWEDISH SUBSIDUARY: GENTIAN DIAGNOSTICS AB

Moss, 8 March 2017

Gentian Diagnostics AS (OSE: GENT-ME) is pleased to announce that

Dr. Aleksandra Mandic Havelka has joined the company as Managing

Director of the Swedish subsidiary, Gentian Diagnostics AB in

Stockholm. The establishment of Gentian Diagnostics AB is the first

step in Gentian's strategy to build a more direct presence in the

Nordic market within the clinical laboratory segment, the veterinary

market as well as in point of care.

Dr. Mandic Havelka comes from the position as a Clinical Biochemist

and Unit Manager at the Clinical Chemistry Department at Karolinska

University Laboratory, Karolinska University Hospital in Stockholm.

She is a molecular biologist and holds a PhD in experimental

oncology. She has several years of experience from both management

positions, and from introducing clinical biomarkers in laboratory

routine. She has also held a central position in national Swedish

quality assessment programs as a chairman for the advisory group for

Protein analysis in the Swedish organization for external quality

assessment, Equalis.

Taking on the responsibility for Gentian Diagnostics AB, Dr. Mandic

Havelka will leverage her market knowledge and user competence. She

is a reputed professional in the clinical chemistry community in

Sweden. Here she will play a major role in clinical demonstrations

of Gentian's new product launches in Swedish Hospitals. Her

competence will also be key in introducing both Gentian's and third

party products in the Nordic laboratory markets.

For further information, please contact:

Bård Sundrehagen

CEO, Gentian Diagnostics AS

E-mail: Bard.sundrehagen@gentian.no

Cell Phone: +47 924 14 117

ABOUT GENTIAN DIAGNOSTICS AS

Gentian Diagnostics AS is a medical diagnostics company listed on

Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME".

Gentian is headquartered in Moss, Norway, with a representative

office in China and distribution subsidiaries in Sweden and USA.

Gentian designs, develops and markets in vitro diagnostic reagents

(IVD) based on its proprietary Nanosense technology. The goal is to

offer efficient and accurate reagents for major clinical chemistry

platforms with a focus within the areas of kidney disease, cardiac

disease, inflammation and veterinary medicine. The Nanosense

technology will enable users to move assays from low volume

immunology platforms to fully automated, high throughput instruments

with shorter turnaround times, better workflow and improved cost

efficiency.